

## Das Polyzystische Ovarsyndrom mit Blick auf kardiometabolische Gesundheit

L. van Baal, D. Führer, S. Tan

### Literatur:

1. International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023. Monash University. <https://doi.org/10.26180/24003834.v1> [https://www.monash.edu/\\_\\_data/assets/pdf\\_file/0003/3379521/Evidence-Based-Guidelines-2023.pdf](https://www.monash.edu/__data/assets/pdf_file/0003/3379521/Evidence-Based-Guidelines-2023.pdf) (zuletzt abgerufen: 05.04.2024)
2. Joham AE et al. Polycystic ovary syndrome. *Lancet Diabetes Endocrinol* 2022; 10(9): 668–80. Erratum in: *Lancet Diabetes Endocrinol* 2022; 10(11): e11
3. Stepto NK et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulinaemic clamp. *Hum Reprod* 2013; 28(3): 777–84
4. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. *Nat Rev Endocrinol* 2018; 14(5): 270–84
5. Rotterdam EA-SPcwg. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 2004; 19(1): 41–7
6. Moghetti P et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. *J Clin Endocrinol Metab* 2013; 98(4): E628–37
7. Hoeger KM et al. Update on PCOS: Consequences, Challenges, and Guiding Treatment. *J Clin Endocrinol Metab* 2021; 106(3): e1071–e83
8. Cassar S et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. *Hum Reprod* 2016; 31(11): 2619–31
9. Hahn S et al. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. *Horm Metab Res* 2005; 37(7): 438–44
10. Zhu T & Goodarzi MO. Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization. *J Clin Endocrinol Metab* 2022; 107(3): e899–e911
11. Tan S et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). *BMC Med Genet* 2010; 11(12): 1471–2350
12. Wojciechowski P et al. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. *Diabetologia* 2012; 55(10): 2636–45
13. Poston L et al. Preconceptional and maternal obesity: epidemiology and health consequences. *Lancet Diabetes Endocrinol* 2016; 4(12): 1025–36
14. Powell-Wiley TM, Poirier P. et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation* 2021; 143(21): e984–e1010
15. Haase CL et al. Association between body mass index, weight loss and the chance of pregnancy in women with polycystic ovary syndrome and overweight or obesity: a retrospective cohort study in the UK. *Hum Reprod* 2023; 38(3): 471–81

16. Kakoly NS et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. *Hum Reprod Update* 2018; 24(4): 455–67
  17. Mills G et al. Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies. *Hum Reprod* 2020; 35(7): 1666–74
  18. Amiri M et al. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. *Reprod Biol Endocrinol* 2020; 18(1): 23
  19. Paschou SA et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. *Endocrine* 2020; 67(1): 1–8
  20. Rocha ALL et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. *J Endocrinol Invest* 2017; 40(12): 1279–88
  21. Kim JJ et al. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2017; 45(11): 1403–12
  22. Sarkar M et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. *Liver Int* 2020; 40(2): 355–59
  23. Tan S et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. *J Clin Endocrinol Metab* 2010; 95(1): 343–8
  24. Roeb E et al. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), April 2022, AWMF-Registernummer: 021–025. *Z Gastroenterol* 2022; 60(9): 1346–421
  25. Hanem LGE et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial. *Lancet Child Adolesc Health* 2019; 3(3): 166–74
  26. Tan S et al. Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial. *Diabetes Obes Metab* 2021; 23(11): 2595–9
- 

## Wechselseitige Beziehung zwischen Schilddrüsenerkrankungen und Diabetes

*K. Müssig*

### Literatur:

1. Nationale Diabetes-Surveillance am Robert Koch-Institut. Diabetes in Deutschland – Bericht der Nationalen Diabetes-Surveillance 2019; RKI Berlin
2. Reiners C et al. Prevalence of thyroid disorders in the working population of Germany: Ultrasonography screening in 96,278 unselected employees. *Thyroid* 2004; 14: 926–32
3. Khattak RM et al. Monitoring the prevalence of thyroid disorders in the adult population of Northeast Germany. *Popul Health Metr* 2016; 14: 39
4. Krebs in Deutschland für 2019/2020. 14. Ausgabe RKI GEKID e.V. Berlin 2023
5. Güney E et al. Thyroid Disease in Diabetes Mellitus. *Turkish Journal of Endocrinology and Metabolism* 1999; 3: 119–22

6. Díez JJ et al. Prevalence of thyroid dysfunction in patients with type 2 diabetes. *Exp Clin Endocrinol Diabetes* 2011; 119: 201–7
7. Díez JJ & Iglesias P. An analysis of the relative risk for goitre in euthyroid patients with type 2 diabetes. *Clin Endocrinol* 2014; 80: 356–61
8. Tseng CH. Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus. *Eur J Endocrinol* 2019; 180: 365–72
9. Barmpari ME et al. Thyroid Dysfunction among Greek Patients with Type 1 and Type 2 Diabetes Mellitus as a Disregarded Comorbidity. *J Diabetes Res* 2017; 6505814
10. Pimenta WP et al. Associação de tireopatias em uma população de pacientes com diabetes. *Arquivos Brasileiros de Endocrinologia e Metabologia* 2005; 49: 234–40
11. Al-Attas OS et al. Urinary iodine is associated with insulin resistance in subjects with diabetes mellitus type 2. *Exp Clin Endocrinol Diabetes* 2012; 120: 618–22
12. Karakaya RE et al. Determining the relationship between dietary iodine intake, urinary iodine excretion and thyroid functions in people with type 2 diabetes mellitus. *Arch Endocrinol Metab* 2020; 64: 383–9
13. SteiB JO et al. Schilddrüsen-sonographie und Harnjodidausscheidung bei Kindern und Jugendlichen mit Diabetes mellitus Typ I. *Klin Padiatr* 1996; 208: 327–33
14. Karaköse M et al. Frequency of nodular goiter and autoimmune thyroid disease and association of these disorders with insulin resistance in polycystic ovary syndrome. *J Turk Ger Gynecol Assoc* 2017; 18: 85–9
15. Dos Santos PB et al. Effects of Metformin on TSH Levels and Benign Nodular Goiter Volume in Patients Without Insulin Resistance or Iodine Insufficiency. *Front Endocrinol* 2019; 10: 465
16. Miranda-Filho A et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. *Lancet Diabetes Endocrinol* 2021; 9: 225–34
17. Dorak MT, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. *Front Genet* 2012; 3: 268
18. Siegel RL et al. Cancer Statistics. *CA Cancer J Clin* 2017; 67: 7–30
19. Lim H et al. Trends in Thyroid Cancer Incidence and Mortality in the United States 1974-2013. *JAMA* 2017; 317: 1338–48
20. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States 1973-2002. *JAMA* 2006; 295: 2164–7
21. Haymart MR et al. Thyroid Ultrasound and the Increase in Diagnosis of Low-Risk Thyroid Cancer. *J Clin Endocrinol Metab* 2019; 104: 785–92
22. Vaccarella S et al. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. *N Engl J Med* 2016; 375: 614–7
23. Enewold L et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics 1980-2005. *Cancer Epidemiol Biomarkers Prev* 2009; 18: 784–91
24. Fiore M et al. Role of Emerging Environmental Risk Factors in Thyroid Cancer: A Brief Review. *Int J Environ Res Public Health* 2019; 16: 1185
25. Aschebrook-Kilfoy B et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. *Thyroid* 2011; 21: 957–63
26. Dong WW et al. Different types of diabetes mellitus and risk of thyroid cancer: A meta-analysis of cohort studies. *Front Endocrinol* 2022; 13: 971213

27. Yeo Y et al. Diabetes mellitus and risk of thyroid cancer: a meta-analysis. *PLoS One* 2014; 9: e98135
28. Li H, Qian J. Association of diabetes mellitus with thyroid cancer risk: A meta-analysis of cohort studies. *Medicine* 2017; 96: e8230
29. Müssig K, Häring HU. Insulin signal transduction in normal cells and its role in carcinogenesis. *Exp Clin Endocrinol Diabetes* 2010; 118: 356–9
30. Müssig K et al. Diabetes, Insulin, Insulinanaloga und Krebs. *Dtsch Med Wochenschr* 2010; 135: 924–9
31. Lammers R et al. Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. *EMBO J* 1989; 8: 1369–75
32. Kellerer M et al. Insulin- and insulin-like growth factor-I receptor tyrosine-kinase activities in human renal carcinoma. *Int J Cancer* 1995; 62: 501–7
33. Moller DE et al. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. *Mol Endocrinol* 1989; 3: 1263–9
34. Tamez-Pérez HE et al. The rate of primary hypothyroidism in diabetic patients is greater than in the non-diabetic population. An observational study. *Med Clin* 2012; 138: 475–7
35. Haymart MR et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. *J Clin Endocrinol Metab* 2008; 93: 809–14
36. Fiore E et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. *Endocr Relat Cancer* 2009; 16: 1251–60
37. Almquist M et al. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project. *Cancer Causes Control* 2011; 22: 743–51
38. Rapp K et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. *Diabetologia* 2006; 49: 945–52
39. Stocks T et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project: analysis of six prospective cohorts. *PLoS Med* 2009; 6: e1000201
40. Lopez R et al. Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin/IGF1R signaling and activation of AKT/mTOR. *PLoS One* 2013; 8: e79708
41. Moreno-Sánchez R et al. Energy metabolism in tumor cells. *FEBS J* 2007; 274: 1393–418
42. Díez JJ, Iglesias P. An analysis of the relative risk for hypothyroidism in patients with Type 2 diabetes. *Diabet Med* 2012; 29: 1510–4
43. Han C et al. Subclinical hypothyroidism and type 2 diabetes: a systematic review and meta-analysis. *PLoS One* 2015; 10: e0135233
44. Chaker L et al. Thyroid function and risk of type 2 diabetes: a population-based prospective cohort study. *BMC Med* 2016; 14: 150
45. Roa Dueñas OH et al. Thyroid Function and the Risk of Prediabetes and Type 2 Diabetes. *J Clin Endocrinol Metab* 2022; 107: 1789–98
46. Rong F et al. Association between thyroid dysfunction and type 2 diabetes: a meta-analysis of prospective observational studies. *BMC Med* 2021; 19: 257
47. Chang CH et al. Association between thyroid dysfunction and dysglycaemia: a prospective cohort study. *Diabet Med* 2017; 34: 1584–90

48. Fleiner HF et al. Prevalence of thyroid dysfunction in autoimmune and type 2 diabetes: the population-based HUNT study in Norway. *J Clin Endocrinol Metab* 2016; 101: 669–77
49. Alwan H et al. Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies. *Eur J Endocrinol* 2022; 187: 35–46
50. Toulis KA et al. Maternal subclinical hypothyroidism and gestational diabetes mellitus: a meta-analysis. *Endocr Pract* 2014; 20: 703–14
51. Kent NL et al. Is the link between elevated TSH and gestational diabetes mellitus dependant on diagnostic criteria and thyroid antibody status: a systematic review and meta-analysis. *Endocrine* 2021; 74: 38–49
52. Luo J et al. Association of thyroid disorders with gestational diabetes mellitus: a meta-analysis. *Endocrine* 2021; 73: 550–60
53. Yang Y et al. Thyroid antibodies and gestational diabetes mellitus: a meta-analysis. *Fertil Steril* 2015; 104: 665–71.e3
54. Van den Driessche A et al. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. *Neth J Med* 2009; 67: 376–87
55. Canaris GJ et al. The Colorado thyroid disease prevalence study. *Arch Intern Med* 2000; 160: 526–34
56. Wu T et al. Subclinical thyroid disorders and cognitive performance among adolescents in the United States. *BMC Pediatr* 2006; 6: 12
57. Warncke K et al. Polyendocrinopathy in children, adolescents, and young adults with type 1 diabetes: a multicenter analysis of 28 671 patients from the German/Austrian DPV-Wiss database. *Diabetes Care* 2010; 33: 2010–2
58. Ziegler AG, Bonifacio E. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. *Diabetologia* 2012; 55: 1937–43
59. Umpierrez GE et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. *Diabetes Care* 2003; 26: 1181–5
60. Shun CB et al. Thyroid autoimmunity in Type 1 diabetes: systematic review and meta-analysis. *Diabet Med* 2014; 31: 126–35
61. Frommer L, Kahaly GJ. Type 1 Diabetes and Autoimmune Thyroid Disease-The Genetic Link. *Front Endocrinol* 2021; 12: 618213
62. Peppas M et al. Skeletal muscle insulin resistance in endocrine disease. *J Biomed Biotechnol* 2010; 2010: 527850
63. Maratou E et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. *Eur J Endocrinol* 2009; 160: 785–90
64. Pearce SH et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. *Eur Thyroid J* 2013; 2: 215–28
65. Garber JR et al. American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism In Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Thyroid* 2012; 22: 1200–35
66. Peters KE et al. Prevalence and incidence of thyroid dysfunction in type 1 diabetes, type 2 diabetes and latent autoimmune diabetes of adults: The Fremantle Diabetes Study Phase II. *Clin Endocrinol* 2020; 92: 373–82

67. Celani MF et al. Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with type 2 diabetes mellitus. *Diabetes Res* 1994; 27: 15–5
  68. Franzese A et al. Thyroid autoimmunity starting during the course of type 1 diabetes denotes a subgroup of children with more severe diabetes. *Diabetes Care* 2000; 23: 1201–2
  69. Nderstigt C et al. Incidence and prevalence of thyroid dysfunction in type 1 diabetes. *J Diabetes Complications* 2016; 30: 420–5
  70. Potenza M et al. Excess thyroid hormone and carbohydrate metabolism. *Endocr Pract* 2009; 15: 254–62
  71. American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Care in Diabetes. *Diabetes Care* 2024; 47(1): 258–81
  72. Kalra S et al. Thyroid Dysfunction and Type 2 Diabetes Mellitus: Screening Strategies and Implications for Management. *Diabetes Ther* 2019; 10: 2035–44
- 

## Moderne Adipositas- und Diabetestherapie – Wo stehen wir heute?

*P. Roser, J. Aberle*

### Literatur:

1. Grundy SM. Metabolic Syndrome Pandemic. *Arterioscler Thromb Vasc Biol* 2008; 28(4): 629–36
2. le Roux CW et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet* 2017; 389: 1399–409
3. Yusuf S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004 364: 937–52
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med* 2022; 387(3): 205–16
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med* 2023; 389(24): 2221–32
6. Scherer PE and JA Hill. Obesity, Diabetes, and Cardiovascular Diseases: A Compendium. *Circ Res* 2016; 118(11): 1703–5
7. Justiz, B.d. Sozialgesetzbuch (SGB) Fünftes Buch (V) - Gesetzliche Krankenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477)§34 Ausgeschlossene Arznei-, Heil- und Hilfsmittel. Verfügbar unter: [https://www.gesetze-im-internet.de/sgb\\_5/\\_\\_\\_34.html](https://www.gesetze-im-internet.de/sgb_5/___34.html) (Letzter Zugriff: 17.04.2024)
8. Roser P SS Bajaj, and FC Stanford. International lack of equity in modern obesity therapy: the critical need for change in health policy. *Int J Obes* 2022; 46(9): 1571–72
9. Lean ME et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet* 2018; 391: 541–51
10. Wing RR. Does Lifestyle Intervention Improve Health of Adults with Overweight/Obesity and Type 2 Diabetes? Findings from the Look AHEAD Randomized Trial. *Obesity (Silver Spring)* 2021; 29(8): 1246–58

11. He L et al. Effect of Intensive Lifestyle Intervention on Cardiovascular Risk Factors: Analysis From the Perspective of Long-Term Variability. *J Am Heart Assoc* 2024; 13(3): e030132
12. Look AHEAD Research Group; Gregg E et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol* 2016; 4(11): 913–21
13. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 2015 373(22): 2117–28
14. Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med* 2017; 377(7): 644–57
15. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2016; 375(4): 311–22
16. Marx N et al. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. *Circulation* 2022; 146(24): 1882–94
17. Theofilis P et al. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. *Diabetes Res Clin Pract* 2022; 188: 109927
18. Davies MJ et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 2022; 65(12): 1925–66
19. Jensterle M et al. Effects of liraglutide on obesity-associated functional hypogonadism in men. *Endocr Connect* 2019; 8(3): 195–202
20. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. *Mol Metab* 2021; 46: 101102
21. Lisco G et al. Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned? *Endocr Connect* 2023; 12(11)
22. He L et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *JAMA Intern Med* 2022; 182(5): 513–19
23. Arillotta D et al. GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. *Brain Sci* 2023; 13(11)
24. (EMA), E.M.A. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023. 2023; Verfügbar unter: <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-october-2023> (Letzter Zugriff: 16.04.2024)
25. (EMA), E.M.A. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. 2024; Verfügbar unter: <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024> (Letzter Zugriff: 16.04.2024)
26. Roser P Kommentar zu Adipositas: Tirzepatid sicher und wirksam? *Diabetologie und Stoffwechsel* 2022; 17(06): 439–40
27. Nauck MA and DA D'Alessio. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. *Cardiovasc Diabetol* 2022; 21(1): 169
28. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med* 2022; 387(3): 205–16

29. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. *Nat Med* 2023; 29(11): 2909–18
30. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet* 2021; 398: 1811–24
31. Herrington WG et al. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 2023; 388(2): 117–27
32. Kim JH et al. Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus. *Clin Cardiol* 2024; 47(3): e24248
33. Liu J et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Obes Metab* 2020; 22(9): 1619–27
34. Marfella R et al. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes. *Cardiovasc Diabetol* 2024; 23(1): 10
35. Lingvay I et al. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. *Lancet* 2022; 399: 394–405
36. Schauer PR et al. Clinical Outcomes of Metabolic Surgery: Efficacy of Glycemic Control, Weight Loss, and Remission of Diabetes. *Diabetes Care* 2016; 39(6): 902–11
37. Doumouras AG et al. Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease. *Circulation* 2021; 143(15): 1468–80
38. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. *J Int Med* 2013; 273(3): 219–34
39. Rausa E et al. Rate of Death and Complications in Laparoscopic and Open Roux-en-Y Gastric Bypass. A Meta-analysis and Meta-regression Analysis on 69,494 Patients. *Obes Surg* 2016; 26(8): 1956–63
40. Flum DR et al. Perioperative safety in the longitudinal assessment of bariatric surgery. *N Engl J Med* 2009; 361(5): 445–54
41. Gemeinsamer Bundesausschuss. DMP-Anforderungen 2023, Verfügbar unter: [https://www.g-ba.de/downloads/39-261-6299/2023-11-16\\_DMP-A-RL\\_Anlage-2-23-24-Adipositas.pdf](https://www.g-ba.de/downloads/39-261-6299/2023-11-16_DMP-A-RL_Anlage-2-23-24-Adipositas.pdf)